Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and willingly sign a written consent form
• People aged 18 or older, of any gender
• People who have been confirmed through a tissue or cell sample (with a pathology report) to have a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC) that cannot be surgically removed and is either locally advanced (stage IIIB or IIIC) or has spread to other parts of the body (stage IV)
• People who have not previously received any systemic treatment (such as targeted therapy, chemotherapy, immunotherapy, or experimental drugs) for their advanced or metastatic lung cancer, and for whom surgery or radiotherapy aimed at curing the cancer is not suitable; people who had earlier surgery followed by preventive (adjuvant or neoadjuvant) treatment may be eligible if there was no sign of the cancer returning within 6 months of surgery, and at least 6 months have passed since finishing that earlier treatment
• People who have at least one measurable area of cancer that meets specific measurement standards (RECIST 1.1) at the start of the trial; any previously treated area must show clear signs of the cancer having grown back before it can count; brain tumours cannot be used as the measured target
• People with a general health and activity level rated as 0 or 1 on a standard medical scale (meaning fully active or restricted in strenuous activity only)
• People with an expected survival of at least 3 months
• People whose blood, kidney, liver, and clotting test results fall within specific acceptable ranges when checked within 7 days before the first dose (without recent blood transfusions, growth factor injections, or other supportive treatments that could artificially improve those results — confirm specific required values with the trial site)

Who may not be able to join:

• People whose lung cancer has certain specific genetic mutations (such as ALK, ROS1, KRAS, BRAF, RET, MET, NTRK, or HER2) for which approved targeted treatments are already available, or who have other mutations where the trial investigator judges that they would not benefit from this study
• People who have taken Chinese herbal or patent medicine preparations specifically indicated for lung cancer treatment within the 2 weeks before joining the trial
• People who have received local radiotherapy within the 2 weeks before joining, or who have had extensive or large-area bone marrow radiation within the 4 weeks before joining
• People who currently have fluid around the heart (pericardial effusion), unless it is a small, stable amount that has not changed for at least 2 weeks before joining
• People who have had major surgery or a serious injury within the 4 weeks before starting treatment, or who are expected to need major surgery during the trial (minor procedures such as placing a vascular access line or a needle biopsy are generally permitted)
• People who have cancer that has spread to the membranes around the brain or spinal cord, or who have pressure on the spinal cord, or who have brain metastases causing symptoms or considered unstable — unless those brain metastases have been treated, the person has been stable for at least 2 weeks, and no steroid medication is needed; people with brain metastases that are not causing symptoms may be considered if the trial doctor determines no immediate treatment is needed (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.